MRKMerck Sharp & Dohme LLCRunning, no new patients
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Endometrial Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 710 (planned)
- Started
- Dec 6, 2023
- Main results expected
- Jan 10, 2028
- Fully finished
- Jan 10, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 27 months
Overall Survival (OS)
Measured over: Up to approximately 48 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06132958 · record last updated 2026-08-28 · checked 2026-11-09 15:47 UTC